Preoperative dose of etoricoxib reduces postoperative morphine consumption .
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2013;1(6):18 Acta Orthop. 2012 Dec;83(6):642-7. doi: 10.3109/17453674.2012.747053. Epub 2012 Nov 9A total of 66 patients undergoing elective therapeutic knee arthroscopy were included in this trial to examine the effects of etoricoxib on post operative analgesia and opioid consumption. Patients received either 120 mg of etoricoxib or a placebo. Over the first 24 hours, the total postoperative morphine consumption was higher in the placebo group (24 mg) than the etoricoxib group (9 mg). The etoricoxib group also demonstrated reduced pain intensity levels at rest and patient satisfaction with the analgesia provided was greater during the first postoperative day.
Was the allocation sequence adequately generated?
Was allocation adequately concealed?
Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?
Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?
Blinding Patients: Was knowledge of the allocated interventions adequately prevented?
Was loss to follow-up (missing outcome data) infrequent?
Are reports of the study free of suggestion of selective outcome reporting?
Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?
Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?
Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?
Ja = 1
Ungewiss = 0.5
Nicht relevant = 0
Nein = 0
Die Bewertung der Berichtskriterien bewertet die Transparenz, mit der die Autoren die methodischen und studienspezifischen Merkmale der Studie in der Veröffentlichung angeben. Die Bewertung ist in fünf Kategorien unterteilt, die im Folgenden vorgestellt werden.
4/4
Randomization
3/4
Outcome Measurements
2/4
Inclusion / Exclusion
4/4
Therapy Description
3/4
Statistics
Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65
Der Fragilitätsindex ist ein Instrument, das bei der Interpretation signifikanter Ergebnisse hilft und ein Maß für die Stärke eines Ergebnisses liefert. Der Fragilitätsindex gibt die Anzahl der aufeinanderfolgenden Ereignisse an, die zu einem dichotomen Ergebnis hinzugefügt werden müssen, damit das Ergebnis nicht mehr signifikant ist. Eine kleine Zahl steht für ein schwächeres Ergebnis und eine große Zahl für ein stärkeres Ergebnis.
Warum wurde diese Studie jetzt benötigt?
In order to reduce postoperative morphine consumption, various studies have been conducted on the postoperative or intraoperative use of coxibs. Etoricoxib has the longest duration of analgesic action (lasting 22-24 hours) out of the currently registered COX-2 inhibitors. Several studies have confirmed its capacity to provide pain relief after various types of abdominal and trauma surgeries. However, no data exists on the efficacy of the preoperative administration of a single dose of etoricoxib for the attenuation of postoperative pain after therapeutic knee arthroscopy (performed under general anesthesia). Hence, this study is aimed to determine whether a single preoperative dose of 120 mg etoricoxib before knee arthroscopy would reduce patients’ postoperative opioid consumption.
Was war die wichtigste Forschungsfrage?
Does a single preoperative dose of 120 mg etoricoxib reduce the need for additional opioids after therapeutic arthroscopic knee surgery, measured over 24 hours?
- During the 24 hours, patients who received etoricoxib required 14.7 mg (95% CI: 10.2-19.2) less morphine than the patients who received the placebo (p < 0.001, ANOVA).
- Etoricoxib group demonstrated lower overall pain at rest than the placebo group (p = 0.01, ANOVA), but there was no statistically significant difference for overall pain on movement (p = 0.07).
- Patients who received etoricoxib experienced significantly less pain at rest and on movement at 0, 4, 6, and 24 h.
- The etoricoxib group produced significantly higher patient satisfaction at each time point than the control group (p < 0.001 at 24h).
- The difference in the number of patients suffering adverse events was not statistically significant between the two groups (p = 0.3, Fisher's exact test).
Was sollte ich mir besonders merken?
Patients given 120 mg of etoricoxib before therapeutic arthroscopy had about a 60 percent reduction in morphine consumption and felt less pain during the first 24 postoperative hours. Despite the fact that patients could dose their morphine in accordance to their needs, etoricoxib provided exceptional analgesia; hence, while the placebo group used more than twice the amount of morphine than the intervention group, they had far inferior analgesia and were less satisfied with their analgesic therapy
Wie wird sich dies auf die Behandlung meiner Patienten auswirken?
Premedication with etoricoxib appears to provide a number of possible advantages for patients undergoing knee arthroscopy which include; a reduction in opioid consumption, postoperative pain and an improvement in patient satisfaction. However, the sample size of this study was small and larger trials are required to confirm its findings.
HAFTUNGSAUSSCHLUSS
Der Inhalt dieser Seite dient nur zu Informationszwecken und ist nicht als Ersatz für professionelle medizinische Beratung, Diagnose oder Behandlung gedacht. Wenn Sie eine medizinische Behandlung benötigen, wenden Sie sich immer an Ihren Arzt oder suchen Sie die nächstgelegene Notaufnahme auf. Die Meinungen, Überzeugungen und Standpunkte, die von den Personen auf dieser Seite geäußert werden, spiegeln nicht die Meinungen, Überzeugungen und Standpunkte von OrthoEvidence wider.
0 von 4 monatliche KOSTENLOSE Artikel freigeschaltet
